Edition:
United Kingdom

Basilea Pharmaceutica AG (BSLN.S)

BSLN.S on Swiss Exchange

39.16CHF
20 Aug 2019
Change (% chg)

-- (--)
Prev Close
CHF39.16
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
54,756
52-wk High
CHF62.70
52-wk Low
CHF33.46

Select another date:

Tue, Aug 20 2019

BRIEF-Basilea Pharmaceutica Says H1 Net Loss Narrows To CHF 15.4 Mln

* BASILEA REPORTS SIGNIFICANTLY INCREASED CASH-GENERATING REVENUE, FLAT OPERATING EXPENSES AND REDUCED NET LOSS FOR HALF-YEAR 2019

BRIEF-Basilea Starts Phase 1/2 Study With Derazantinib In Urothelial Cancer

* BASILEA STARTS PHASE 1/2 STUDY WITH DERAZANTINIB IN UROTHELIAL CANCER Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Basilea Extends Phase 2 Study With Derazantinib In Intrahepatic Bile Duct Cancer

* BASILEA EXTENDS PHASE 2 STUDY WITH DERAZANTINIB IN INTRAHEPATIC BILE DUCT CANCER (ICCA) TO INCLUDE PATIENTS WITH FGFR2 GENE MUTATIONS OR AMPLIFICATIONS

BRIEF-Basilea Pharmaceutica Publishes Clinical Data For Anticancer Drug Candidates BAL101553

* REPORTS PUBLICATION OF CLINICAL DATA FOR ANTICANCER DRUG CANDIDATES BAL101553 IN GLIOBLASTOMA AND DERAZANTINIB IN INTRAHEPATIC CHOLANGIOCARCINOMA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Select another date: